-
Publication Venue For
-
Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply..
55:1590-1591.
2022
-
Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply..
55:1220-1221.
2022
-
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome..
55:1311-1319.
2022
-
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development..
55:1028-1037.
2022
-
Trends in statin utilisation in US adults with non-alcoholic fatty liver disease..
54:1481-1489.
2021
-
Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications..
54:988-998.
2021
-
Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease..
54:441-450.
2021
-
Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors' reply..
54:198-199.
2021
-
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation..
54:98-108.
2021
-
Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply..
53:1153-1154.
2021
-
Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value..
53:1126-1137.
2021
-
Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms..
53:968-976.
2021
-
Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease..
53:722-732.
2021
-
Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply..
53:652-653.
2021
-
Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms..
53:253-264.
2021
-
Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia..
53:8-21.
2021
-
Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement..
52:923-924.
2020
-
Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria..
52:762-773.
2020
-
Editorial: minesapride for irritable bowel syndrome with constipation..
52:713-714.
2020
-
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis..
52:619-636.
2020
-
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence..
51:1384-1396.
2020
-
Commentary: estimating the prevalence of IBS globally-past, present and future..
51:198-199.
2020
-
Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?.
51:179-180.
2020
-
Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?.
50:825-826.
2019
-
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia..
50:609-610.
2019
-
Editorial: older patients are significantly more likely to have colon ischaemia-associated conditions that are chronic and complex..
50:329-330.
2019
-
Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome..
50:240-248.
2019
-
Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply..
49:1254-1255.
2019
-
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial..
49:1205-1213.
2019
-
Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors..
49:1195-1204.
2019
-
Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome..
48:1044-1060.
2018
-
Editorial: measuring hypervigilance and anxiety in oesophageal disorders..
47:1559-1560.
2018
-
Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits?.
47:1553-1554.
2018
-
Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply..
47:1221-1222.
2018
-
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy..
47:1001-1011.
2018
-
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis..
47:645-656.
2018
-
Genetic risk factors for perception of symptoms in GERD: an observational cohort study..
47:289-297.
2018
-
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration..
47:268-278.
2018
-
Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation?.
46:697.
2017
-
Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply..
46:633-634.
2017
-
Letter: inconsistency in reporting of hypophosphatemia after intravenous iron..
46:641-643.
2017
-
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin..
46:461-462.
2017
-
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease..
46:389-400.
2017
-
Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply..
45:1268-1269.
2017
-
Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply..
45:1176.
2017
-
Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis..
45:824-832.
2017
-
Letter: causes of fatigue in inflammatory bowel disease remain uncertain..
45:762-763.
2017
-
Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?.
45:563-564.
2017
-
Non-alcoholic fatty liver diseases and risk of colorectal neoplasia..
45:345-353.
2017
-
Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care..
45:91-99.
2017
-
The learning curve for interpretation of oesophageal high-resolution manometry: a prospective interventional cohort study..
45:291-299.
2017
-
The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease..
45:63-74.
2017
-
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms..
44:1253-1264.
2016
-
Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease..
44:890-898.
2016
-
Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders - brain-gut, gut-brain, or both?.
44:899-900.
2016
-
Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome..
44:246-258.
2016
-
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis..
44:157-169.
2016
-
Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis..
44:117-126.
2016
-
Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply..
43:1246.
2016
-
Letter: deleterious effects of smoking on post-operative Crohn's disease - authors' reply..
43:1248.
2016
-
Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease..
43:549-561.
2016
-
Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease..
43:440.
2016
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers..
43:356-363.
2016
-
Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption--authors' reply..
42:781.
2015
-
Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers..
42:491-503.
2015
-
Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea..
42:3-11.
2015
-
Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome..
41:1222-1223.
2015
-
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease..
41:1227-1236.
2015
-
Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply..
41:791-792.
2015
-
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir..
41:671-685.
2015
-
Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating..
41:449-458.
2015
-
Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care--authors' reply..
40:1244-1245.
2014
-
Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients..
40:827-834.
2014
-
The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care..
40:382-391.
2014
-
Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care..
40:216.
2014
-
Letter: is there a bi-directional relationship between depression and IBD?.
40:213.
2014
-
Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease..
40:3-15.
2014
-
Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease..
39:447-458.
2014
-
Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria..
39:312-321.
2014
-
Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding..
39:346.
2014
-
Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument..
37:750.
2013
-
The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study..
37:323-331.
2013
-
NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people..
37:195-203.
2013
-
Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD..
36:207.
2012
-
Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience..
35:284-291.
2012
-
Is otilonium bromide globally effective in irritable bowel syndrome?.
34:1034-1035.
2011
-
Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience..
34:405-407.
2011
-
Meta-analysis: Coeliac disease and hypertransaminasaemia..
34:33-40.
2011
-
Meta-analysis: the epidemiology of noncardiac chest pain in the community..
34:172-180.
2011
-
Do dried plums really help constipation?.
33:1258-1259.
2011
-
Systematic review: the effects of fibre in the management of chronic idiopathic constipation..
33:895-901.
2011
-
Defining a responder in treatment trials for chronic idiopathic constipation..
33:285-286.
2011
-
A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus..
32:1332-1342.
2010
-
Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience..
32:1357-1363.
2010
-
Effect of oral zinc in hepatic encephalopathy remains unclear..
32:1405-1406.
2010
-
Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis..
32:1297-1306.
2010
-
Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates..
32:1294-1295.
2010
-
Reporting of relapse rates in a trial of mesalazine for ulcerative colitis..
32:1205-1206.
2010
-
Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus..
32:795-800.
2010
-
Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?.
32:612-613.
2010
-
Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome..
32:144-158.
2010
-
Renzapride in IBS: is efficacy in the eye of the beholder?.
32:113-114.
2010
-
Systematic review: prognostic tests of paracetamol-induced acute liver failure..
31:1064-1076.
2010
-
Alverine citrate, simeticone, and Rome III irritable bowel syndrome..
31:767-768.
2010
-
Probiotics in irritable bowel syndrome: underachievers or underpowered?.
31:922-923.
2010
-
Applicability of the reported prevalence of bile salt malabsorption in irritable bowel..
31:161-162.
2010
-
Generalized anxiety disorder and irritable bowel syndrome..
30:1087-1088.
2009
-
10-biomarker algorithm to identify irritable bowel syndrome..
30:95-96.
2009
-
Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia..
30:28-36.
2009
-
Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study..
28:1013-1020.
2008
-
Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia..
28:534-544.
2008
-
Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C..
27:422-432.
2008